On November 30, 2011, Pfizer lost U.S. exclusivity for Lipitor. [1] The FDA approved Ranbaxy’s generic atorvastatin on the same day. [2] By the end of December, brand Lipitor still held just over 37% of atorvastatin prescriptions, according to IMS Health data reported by the Associated Press. [3] A brand usually keeps about 10% of sales after generic competition starts. [4]
That result is the source of the “40% market share” claim. The claim is partly right and often misread. The 40% figure describes prescription share in the first weeks of generic entry. It does not describe revenue, and it did not last.
This article tests the claim against Pfizer’s SEC filings, court records, and market data from IMS Health, Wolters Kluwer, and Goldman Sachs. It then turns the record into a playbook for loss-of-exclusivity (LOE) planning. I use primary documents for every revenue figure and every legal event. I label every calculated figure as analysis. DrugPatentWatch tracks the patent and litigation records that sit behind this kind of timeline. The calculations here use Pfizer, FDA, and court documents only.
The Short Answer
Did Pfizer Really Keep 40% of Lipitor’s Market After Generic Entry?
Yes, for a few weeks, and only by one measure. Brand Lipitor held between 33% and 41% of atorvastatin prescriptions in the first 13 weeks after generic entry, depending on the data source and the week. [3][5][6][7] It did not hold 40% of revenue. U.S. branded Lipitor revenue fell 81% in 2012, from $5,003 million to $932 million. [8]
U.S. branded Lipitor revenue: $5,003 million in 2011 and $932 million in 2012, a decline of 81%. Source: Pfizer Inc. fourth-quarter and full-year 2012 results. [8]
The Six Findings That Matter
Four published sources put brand Lipitor at 33% to 41% of atorvastatin prescriptions between December 2011 and early March 2012. [9][3][5][6]
The 40% figure existed before launch as a planning assumption. Watson’s sales projections assumed Pfizer would keep 40% of the market. [10]
U.S. branded Lipitor revenue in the fourth quarter of 2012 was 7.5% of the fourth quarter of 2011 (analysis, from Pfizer’s reported figures). [8]
The launch date was set 1,260 days (about 3.4 years) in advance. Pfizer and Ranbaxy agreed to November 30, 2011 on June 18, 2008 (analysis). [11]
Pfizer launched the $4 Lipitor copay card in December 2010, about one year before generic entry. [12]
The steepest quarterly revenue drop came after multi-source generic entry in May 2012. U.S. revenue fell 68.2% from the third quarter to the fourth quarter of 2012 (analysis). [1][13][8]
What the Data Shows: Brand Lipitor Share From December 2011 to March 2012
Brand Lipitor Share Measurements Compared
Table 1 lists every share measurement I found for the first 13 weeks. The sources use different data and different denominators. Do not average them.
Brand just over 37%; Ranbaxy about 35%; Watson about 27%
37%
IMS Health, reported by the Associated Press [3][14]
Week ending January 6, 2012
Atorvastatin 67.4% of the Lipitor market
32.6% (derived)
IMS prescription data, reported by Barclays Capital [5]
About 10 weeks after launch
41% of dispensed prescriptions; 35% of payer-approved volume
41% dispensed; 35% approved
Wolters Kluwer Pharma Solutions claims data, February 15, 2012 [7]
Week ending March 2, 2012
Atorvastatin 67.0% of the Lipitor market
33.0% (derived)
IMS prescription data, reported by Barclays Capital [6]
The range is 33% to 41%. The low end comes from IMS data in January and March 2012. The high end comes from the first week of December and from claims data.
Where the 40% Figure Came From
The number appears in planning documents before launch. Watson’s sales projections assumed that Pfizer would keep 40% of the market and that Watson would compete with Ranbaxy. [10] Analysts said Pfizer could keep up to 40% of Lipitor sales in the coming months. [15]
Watson’s chief executive had expected Pfizer to keep about 25% of Lipitor users for six months. He said it now looked like 40% to 45%, according to a November 29, 2011 report. [4] A Pfizer executive said more than a third of patients wanted to stay on Lipitor. [4]
So the 40% figure had three origins: a Watson planning assumption, analyst commentary, and early IMS data. None of them measured revenue.
Four Ways to Measure Share After LOE (Original Framework)
Sources disagree because they measure different things. I use a four-part framework to separate them. This is my own classification, not an industry standard.
Statin-Class Prescription Share
This measure counts Lipitor against all statins. A New England Journal of Medicine analysis reported that Lipitor’s share of the statin market fell from 44% in 2006 to 26% in 2009. Generic simvastatin held 41% in 2009. [12] This measure is the weakest guide to post-LOE behavior, because it includes drugs that Lipitor patients never switch to at the pharmacy counter.
Molecule-Level Prescription Share
This measure counts brand Lipitor against all atorvastatin, including generics. The IMS figures of 37%, 32.6%, and 33.0% use this denominator. [3][5][6] The “40%” claim belongs here.
Claims-Based Dispensed and Approved Share
This measure uses pharmacy claims. Wolters Kluwer reported that Lipitor held 41% of dispensed atorvastatin prescriptions but only 35% of payer-approved volume. [7] The gap shows that plans were already steering patients to generics.
Brand Revenue Retention
This measure compares brand revenue after LOE with brand revenue before LOE. It includes price, rebates, and volume. Pfizer’s first-quarter 2012 U.S. Lipitor revenue was $383 million, against $1,305 million in the first quarter of 2011. [16] That is 29.3% retention (analysis).
Lipitor Patent Timeline: From the ‘893 Compound Patent to the November 30, 2011 Launch
Lipitor Patent and Exclusivity Timeline
Table 2 assembles dates from court records, SEC filings, and Pfizer releases.
Date
Event
Source
1987 onward
Pfizer starts obtaining patents on atorvastatin calcium
Pfizer defended Lipitor patent challenges by Ranbaxy worldwide from 2003. [11] Three U.S. events shaped the outcome.
The August 2006 Federal Circuit Ruling
On August 2, 2006, the Federal Circuit affirmed the validity of the ‘893 patent. It held that claim 6 of the ‘995 patent was invalid. [17] The ‘893 patent (U.S. 4,681,893) covers atorvastatin. A 2008 report put its expiration in March 2010. [22] The Supreme Court denied Ranbaxy’s certiorari petition in April 2007. [17]
The Reissue of the ‘995 Enantiomer Patent
Pfizer sought a reissue of the ‘995 patent to correct a technical defect. [18] The reissue is RE40,667. Pfizer said it kept the same June 2011 expiration date, including six months of pediatric exclusivity. [18] The District of Delaware found Ranbaxy’s counterclaims about the unissued reissue “speculative, purely hypothetical and unripe” on November 29, 2007. [17]
The ‘893 Reexamination Requests
Ranbaxy asked the Patent Office to reexamine the ‘893 patent in July 2007 (No. 90/008,727). The office issued a notice of intent to issue a reexamination certificate in April 2008. Ranbaxy filed a second request on February 22, 2008 (No. 90/009,048). The office denied it on April 9, 2008. [22]
The 2008 Settlement: What It Fixed and What It Did Not
Pfizer announced the Ranbaxy settlement on June 18, 2008. Ranbaxy received a license to sell generic Lipitor and Caduet in the U.S. effective November 30, 2011. Ranbaxy also held 180 days of first-filer exclusivity. [11]
Pfizer listed the remaining patent terms in that release. The basic compound patent expired in 2010. The enantiomer patent expired in 2011. Process and crystalline-form patents expired in 2016 and 2017. The Caduet combination patent expired in 2018. [11]
Pfizer said the settlement contained no reverse payments. [11] Pfizer executive Ian Read called it “a win-win-win because it is pro-patient, pro-competition and pro-intellectual property.” [11]
Plaintiffs later called the agreement a reverse-payment arrangement. The Third Circuit describes that claim in its 2026 opinion. [2] I return to that case below.
Why the License Date Sits Five Months After the June 2011 Expiry
The reissue patent expired in June 2011, but the Ranbaxy license began on November 30, 2011. [18][11] That gap is 155 days if I count from June 28, 2011 (analysis; the sources give only “June 2011”). The NEJM authors reported that the Pfizer-Ranbaxy agreement “reportedly” delayed the first generic’s U.S. launch by five months. [12] I did not find a primary document that explains the gap. Check the Orange Book entries for exact dates before you cite this one.
Why FDA Approval Arrived on Launch Day
Ranbaxy’s license date did not guarantee a product. FDA issued warning letters about Ranbaxy’s Paonta Sahib plant in 2006 and 2008. In February 2009, FDA invoked its Application Integrity Policy and halted review of Ranbaxy’s applications. [2]
FDA granted an exception in May 2011 and expedited review, which took about six and a half months. FDA found the application “substantially complete” in July 2011. FDA repeatedly told Ranbaxy it could not guarantee approval before November 30. [2]
Ranbaxy’s product entered the market on November 30, 2011, the day FDA approved it. [2] FDA’s drug center director, Janet Woodcock, said: “We are working very hard to get generic drugs to people as soon as the law will allow.” [15]
How Pfizer Defended Share: The Four-Lever Playbook (Original Framework)
Pfizer used four levers at the same time. I group them as contracting, patient assistance, an authorized generic, and date control. This grouping is my own analysis.
Lever 1: Exclusive Dispensing Contracts With PBMs and Insurers
Pfizer offered rebates so that some insurers and pharmacy benefit managers would dispense only Lipitor for six months. Patients paid their plan’s generic copay or $4. [4] Medco Health Solutions was named in the report. A Medco executive, Tim Wentworth, said the deal would save clients and members “over $1 billion just on this drug” in the next year. [4]
The NEJM authors described the same structure. Pfizer agreed with PBMs and insurers to provide Lipitor below the generic price, with generic-level copays, in return for exclusive atorvastatin prescriptions. [12]
Not every payer accepted. Some PBMs and plans reportedly rejected Pfizer’s offer and kept the generic. [23]
Lever 2: The $4 Copay Card
Pfizer launched the “Lipitor for You” card in December 2010 and set it to expire in December 2012. [12] Insured patients could get Lipitor for $4 a month. A preferred brand copay averaged $25, and a generic copay averaged $10. [4]
NPR reported the same $4 figure and noted that the average brand copay without the card was about $25. [9] Pfizer also paid pharmacies to mail card offers and to counsel patients on Lipitor’s benefits. [4]
The launch date matters. The card began 364 days before generic entry (analysis, counting from December 1, 2010, because the source gives only the month). [12] Pfizer enrolled patients before the pricing change.
Lever 3: The Watson Authorized Generic
Pfizer granted Watson Pharmaceuticals the exclusive right to sell the authorized generic of Lipitor in the U.S. for five years, starting November 30, 2011. [20] Pfizer manufactures all strengths and supplies Watson. Watson markets and distributes the product. Pfizer receives a share of Watson’s net sales. The agreement runs until November 30, 2016. [19]
One report said Pfizer keeps an estimated 70% of the authorized generic’s price. [4] That is an estimate in a news report, not a disclosed contract term.
In the first few days, Watson took 97.6% of generic atorvastatin sales, according to a report relayed by Fierce Pharma. Watson and Ranbaxy together held roughly 14.6% of atorvastatin prescription volume. Ranbaxy held about 2.5%. [24] The sources do not explain the gap, and the two figures cover different periods. By the end of December, IMS data showed Ranbaxy at about 35% and Watson at about 27%. [14]
Pfizer’s earnings releases credit the Watson agreement with a positive effect on Established Products revenue. They do not give a separate authorized-generic revenue figure. [16]
Lever 4: Control of the Entry Date
Pfizer used the 2008 settlement to fix the date of generic entry. The press release said the agreement gave “substantial certainty regarding the potential date November 30, 2011.” [11] A fixed date let Pfizer build contracts, copay inventory, and a supply deal around one day.
Pharmacy Economics During the 180 Days
Pharmacy reimbursement typically falls only 10% to 15% in the first 180 days after generic launch, while acquisition cost falls faster. This is more pronounced with an authorized generic. Pharmacy gross profit per prescription almost doubles in the window. [23] A McKesson analyst-day slide from June 2011 indicates wholesalers earn two to three times as much on a generic in that period. [23]
Pfizer priced the brand against that profit pool. Its statement said Lipitor would be priced “at or below the cost of a generic.” [15]
Payer Pushback in the First Ten Weeks
Wolters Kluwer reported that rejected Lipitor claims rose to nearly 8% in December. Patient reversals rose to nearly 10%. The firm said the increase shows plans moving patients to generics. [7] A report analyst said Lipitor volume would likely keep falling because its 35% payer-approval share sat below its 41% dispensed share. [7]
Marketing Spend Before LOE
From July through September 2011, Pfizer spent almost $90 million on doctor sales calls and samples. Patient-directed advertising fell about 60% to $19 million. [4]
Pfizer’s Organizational Move
Starting in 2012, Pfizer reported U.S. Lipitor sales in its Established Products business unit. [1] David Simmons, head of that unit, said more than a third of patients wanted to stay on Lipitor. [4]
What the Revenue Shows: Lipitor Quarterly Revenue, 2011 and 2012
Quarterly Revenue Table and Calculated Retention
Table 3 lists Pfizer’s reported branded Lipitor revenue by quarter. The retention column is my calculation.
Quarter
U.S. 2011
U.S. 2012
U.S. retained (analysis)
Worldwide 2011
Worldwide 2012
Worldwide retained (analysis)
Q1
1,305
383
29.3%
2,385
1,395
58.5%
Q2
1,412
296
21.0%
2,591
1,220
47.1%
Q3
1,470
192
13.1%
2,602
749
28.8%
Q4
816
61
7.5%
1,999
584
29.2%
Full year
5,003
932
18.6%
9,577
3,948
41.2%
Sources: first quarter [16], second quarter [25], third quarter [13], fourth quarter and full year [8]. The quarters sum to the reported annual totals. I checked that sum.
Sequential Decline: When the Revenue Fell
Sequential change shows the timing. Using Pfizer’s quarterly U.S. figures, I calculate the following changes from the prior quarter.
Q4 2011 against Q3 2011: down 44.5%, to $816 million from $1,470 million. Generic entry covered only December.
Q1 2012 against Q4 2011: down 53.1%, to $383 million.
Q2 2012 against Q1 2012: down 22.7%, to $296 million.
Q3 2012 against Q2 2012: down 35.1%, to $192 million.
Q4 2012 against Q3 2012: down 68.2%, to $61 million.
The last two drops follow multi-source entry. Pfizer’s 2012 filing says multi-source generic competition in the U.S. began in May 2012. [1] The share-defense levers targeted the 180-day window. The revenue record shows no protection after that window.
U.S. Versus International Revenue
U.S. revenue accounted for 52.2% of worldwide Lipitor revenue in 2011 and 23.6% in 2012 (analysis). The U.S. decline of $4,071 million explains 72.3% of the worldwide decline of $5,629 million (analysis). International revenue fell 34%, from $4,574 million to $3,016 million. [8]
The international losses came on a different schedule. Lipitor lost exclusivity in Japan in June 2011, Australia in April 2012, and most of developed Europe in March and May 2012. [1] Pfizer’s 2011 filing says the European compound patent expired in November 2011, and pediatric extensions carried exclusivity in most major European markets to May 2012. [20]
Revenue Retained Versus Share Retained: A Scenario
Brand Lipitor held 33% to 41% of atorvastatin prescriptions, yet first-quarter 2012 U.S. revenue was 29.3% of the prior-year quarter. The difference comes from lower net price per prescription and from volume lost to generics. I can bound the price effect with a scenario. This is analysis, not a reported statistic.
Assumptions: total atorvastatin prescriptions in Q1 2012 equal Q1 2011. Pfizer’s branded revenue line excludes authorized-generic revenue. Reported revenue matches dispensed volume with no inventory effects. These assumptions are simplifications.
Assumed brand share of atorvastatin prescriptions
Revenue retained (reported)
Implied net revenue per brand prescription
33%
29.3%
about 89% of the prior level
37%
29.3%
about 79% of the prior level
41%
29.3%
about 71% of the prior level
The scenario suggests that net price per prescription fell by roughly 11% to 29%. Profit fell faster than revenue. A Sanford Bernstein analyst estimated that Pfizer’s profit on a 90-day supply would fall from about $225 to about $100 even after rebates. [4] That is a profit estimate, and it does not compare directly with the revenue scenario.
Lipitor vs. Generic Zocor: The Price Curve After Entry
The NEJM authors projected generic atorvastatin pricing from generic Zocor history. Generic Zocor was priced at 84% of the brand one month after entry, 81% at six months, 40% at 12 months, and 39% at 36 months. [12] The authors projected generic atorvastatin at about 82% of the brand price at entry and about 49% after the six-month exclusivity period. [12] These are projections, not observed Lipitor prices.
The pattern explains why the 180-day window mattered to Pfizer. Prices stay high while one or two generics share the market. They fall after the window closes.
Who Else Won in the 180-Day Window: Ranbaxy, Watson, and Teva
Ranbaxy’s First-Filer Position
Ranbaxy held 180 days of exclusivity and shared part of its exclusivity profit with Teva. [15] A June 2012 report said Ranbaxy reportedly earned about $600 million from generic atorvastatin during exclusivity. It said Teva reportedly made about $300 million under its November 2011 agreement with Ranbaxy. [26] Both figures are press reports. I did not find them in Ranbaxy’s or Teva’s filings.
Teva’s Decision Not to Launch
Teva had FDA tentative approval at the end of 2011 and chose not to market its own generic atorvastatin. Its U.S. chief executive, William Marth, said: “we’ve made a really hard choice on not launching atorvastatin.” He said the decision would cost about $150 million. [26] Marth cited a crowded market, with eight companies planning generic Lipitor versions, and capacity use. [26]
Supply Quality: The November 2012 Ranbaxy Recall
Ranbaxy notified customers of a voluntary recall on November 9, 2012. FDA’s notice lists 41 lots of 10 mg, 20 mg, and 40 mg atorvastatin tablets. The reason was possible contamination with glass particles smaller than 1 mm. Ranbaxy stopped making atorvastatin until it found the cause. [21]
FDA said the chance of adverse health problems was “extremely low” and did not expect a drug shortage. It noted that other manufacturers supplied atorvastatin. [21] The event shows a risk for first filers: a single-source launch depends on one plant. By November 2012, other suppliers had entered. [1]
The FTC’s Authorized Generic Data: What Lipitor Tells Us
What the FTC Found About Authorized Generics
The FTC’s August 31, 2011 report found that an authorized generic cuts the first filer’s average revenue by 40% to 52% during the 180-day exclusivity period. For the first 30 months after exclusivity, first-filer revenue is 53% to 62% lower. Retail prices are 4% to 8% lower with an authorized generic. Wholesale prices are 7% to 14% lower. [27]
The report found that the lower revenue has not substantially reduced the number of generic challenges to branded drug patents. [27]
How the Lipitor Case Differs From a No-AG Settlement
The FTC also reviewed settlements in which a brand promised not to launch an authorized generic while the first filer agreed to defer entry. About 25% of first-filer settlements from fiscal year 2004 to 2010 included such terms. [27] Lipitor was the opposite case. Pfizer launched an authorized generic through Watson on day one. [19] Ranbaxy competed with it. That design cut the first filer’s take and kept more volume under Pfizer’s control.
In re Lipitor Antitrust Litigation: The 2026 Third Circuit Decision
What the Court Held
On August 13, 2026, the Third Circuit issued a non-precedential opinion in In re Lipitor Antitrust Litigation (MDL No. 2332). It affirmed summary judgment for Ranbaxy and the denial of class certification. [2]
The court held that plaintiffs lacked antitrust standing. They did not show that, without the Pfizer-Ranbaxy settlement, FDA more likely than not would have approved Ranbaxy’s generic before November 30, 2011. Evidence that approval “may” have come earlier was not enough. [2]
What the Opinion Does Not Decide
The panel did not rule on whether the settlement was an unlawful reverse payment. It decided causation and standing. [2] The opinion records that Ranbaxy paid Pfizer $1 million to settle the Accupril litigation. It also records that Pfizer settled with plaintiffs before the district court ruled. [2]
For LOE planners, the lesson is about proof. The court treated FDA’s review timeline, not the settlement date, as the controlling question. The appellate ruling came about 14.7 years after generic entry (analysis, from November 30, 2011 to August 13, 2026). [2]
What This Means for Brand Manufacturers
A Seven-Step LOE Checklist Drawn From the Lipitor Record
These steps are my analysis. Each links to a documented Lipitor action.
Fix the entry date early. Pfizer set it 1,260 days ahead. [11]
Start patient assistance before LOE. Pfizer’s copay card began about one year ahead. [12]
Sign the authorized-generic partner before the launch date. The Watson term was five years. [20]
Offer payers a reason to contract. Pfizer priced Lipitor at or below the generic cost. [15]
Move the product to a dedicated unit. Pfizer reported U.S. Lipitor in Established Products from 2012. [1]
Track share and revenue as separate numbers. Lipitor held about a third of prescriptions and lost 81% of U.S. revenue. [6][8]
Plan for the second drop. U.S. revenue fell 68.2% sequentially in the fourth quarter of 2012 (analysis). [8][13]
When the Lipitor Playbook Does Not Transfer
The playbook relied on four conditions in 2011. Patients took Lipitor daily. Payers had a generic option priced near the brand. Pharmacies earned more on generics in the window. A third of patients preferred the brand. [4][23] I did not test whether each lever works under current rules for copay assistance, rebates, or Medicare Part D. Check current rules before you copy a lever.
What the Playbook Bought
The playbook bought time in the exclusivity window. Pfizer’s U.S. branded revenue in the first quarter of 2012 was $383 million, which is 29.3% of the prior-year quarter (analysis). [16] That is far above the 10% retention that a typical brand keeps. [4] The comparison mixes revenue and sales share, so treat it as directional.
The franchise did not survive in the U.S. Pfizer’s U.S. branded revenue in 2012 was $932 million. [8] Today, Viatris lists Lipitor among 20 primarily off-patent oral solid dose legacy brands in its Upjohn business. [28] Viatris also lists Lipitor as a significant product in Greater China, where volume-based procurement covers about 490 molecules. [28]
What This Means for Generic Manufacturers and Payers
For First Filers
Plan for an authorized generic on day one. The FTC data put the first-filer revenue loss at 40% to 52% in the window. [27] Plan for supply risk, because one plant carried the launch. [21] Plan for FDA timing. Ranbaxy’s application sat under an integrity-policy hold from February 2009. [2]
For Later Entrants
Teva’s choice shows that a tentative approval is not a launch decision. Capacity, pack sizes, and crowding can change the economics. [26] Multi-source entry in May 2012 brought price pressure that the brand’s contracts did not cover. [1]
For Payers and PBMs
Payers had two numbers to watch. Dispensed share was 41%, and approved share was 35%. [7] A plan that approves fewer brand claims than pharmacies fill is moving patients, but slowly. Medco’s executive claimed the contract would save “over $1 billion just on this drug” in 2012. [4] That is a company claim in a news report, not an audited figure.
How to Track an LOE Like Lipitor: A Data Workflow
Which Records to Pull
An LOE timeline needs four record types: listed patents and exclusivities, litigation dockets and settlement terms, FDA approvals and tentative approvals, and sales data from company filings. DrugPatentWatch aggregates Orange Book patent and exclusivity entries, Paragraph IV certifications, and litigation records for this purpose. Use it to build the first draft of the timeline. Then confirm each date against the Orange Book, the court opinion, or the SEC filing.
Why a Single Expiry Date Is Not an LOE Date
Lipitor shows three different dates for one product. The reissue patent expired in June 2011. [18] The Ranbaxy license began on November 30, 2011. [11] Multi-source competition began in May 2012. [1] A model that uses only the first date misses six months of single-generic pricing and the later price drop.
Methodology and Limitations
Data and Selection
I used Pfizer press releases and SEC filings for revenue, a Third Circuit opinion for litigation and FDA review facts, and FDA for the recall. I used news reports and trade-press analyses for share data and deal terms when no primary source existed. I reviewed share measurements published from November 2011 to March 2012. I included every measurement I found. I excluded undated claims.
Calculations
Retention equals the 2012 figure divided by the 2011 figure for the same quarter. Sequential change equals the quarter’s figure divided by the prior quarter’s figure, minus one. Derived brand share equals 100% minus the reported atorvastatin share of the Lipitor market. Day counts use calendar days between the cited dates. I used the first day of a month where a source gave only a month. I labeled each calculation as analysis in the text.
Limitations
Pfizer’s branded Lipitor line excludes the authorized-generic revenue that Pfizer receives from Watson. The releases I reviewed give no separate figure. [16]
I did not find public IMS or claims-based Lipitor share data after March 2012.
News reports in this article are secondary sources. Where I could not read the underlying data, I say so.
The scenario in Table 4 depends on assumptions that I state. It is not a reported statistic.
Key Takeaways
Brand Lipitor held 33% to 41% of atorvastatin prescriptions in the first 13 weeks after generic entry. [9][3][5][6][7]
The 40% figure started as a Watson planning assumption and analyst estimate before launch. [10][15]
U.S. branded Lipitor revenue fell 81% in 2012, to $932 million from $5,003 million. [8]
U.S. revenue in the fourth quarter of 2012 was 7.5% of the prior-year quarter (analysis). [8]
Pfizer used four levers: exclusive dispensing contracts, a copay card, an authorized generic, and a fixed entry date. [4][12][19][11]
The steepest sequential decline followed multi-source entry in May 2012. [1][13][8]
The Third Circuit affirmed judgment for Ranbaxy on August 13, 2026, on standing and causation grounds. [2]
FAQ
What was Lipitor’s U.S. loss of exclusivity date?
Pfizer lost U.S. exclusivity for Lipitor on November 30, 2011. [20] Ranbaxy’s license under the 2008 settlement took effect that day. [11]
Who sold the first generic Lipitor?
Ranbaxy and Watson both sold generic atorvastatin from November 30, 2011. Ranbaxy sold its own product under first-filer exclusivity. Watson sold Pfizer’s authorized generic. [19][2]
How much did Lipitor’s U.S. revenue fall after generic entry?
U.S. branded Lipitor revenue fell 81% in 2012, from $5,003 million to $932 million. [8] Worldwide revenue fell 59%, from $9,577 million to $3,948 million. [8]
Did Pfizer pay Ranbaxy to delay generic Lipitor?
Pfizer said its 2008 settlement contained no reverse payments. [11] Plaintiffs called it a reverse-payment arrangement. The Third Circuit affirmed judgment for Ranbaxy in 2026 because plaintiffs did not prove earlier FDA approval was more likely than not. It did not rule on whether the settlement was unlawful. [2]
What was the Lipitor copay card?
The “Lipitor for You” card brought a month’s supply of brand Lipitor to as little as $4 with some insurance plans. Pfizer launched it in December 2010. [12][9]
What is an authorized generic?
An authorized generic is the brand product sold under a generic label, here by Watson under a Pfizer supply agreement. [19] The FTC found that an authorized generic cuts a first filer’s revenue by 40% to 52% during the 180-day window. [27]
When did multi-source generic competition start for Lipitor?
Pfizer says multi-source generic competition in the U.S. began in May 2012. [1] Ranbaxy’s 180-day exclusivity was due to end in late May 2012. [20]
Why did Ranbaxy’s FDA approval take so long?
FDA invoked its Application Integrity Policy in February 2009 and halted review of Ranbaxy’s applications. FDA granted an exception in May 2011 and then spent about six and a half months on an expedited review. [2]
Was generic Lipitor ever recalled?
Ranbaxy recalled 41 lots of 10 mg, 20 mg, and 40 mg atorvastatin tablets in November 2012 for possible glass-particle contamination. FDA said the risk of adverse health problems was extremely low and expected no shortage. [21]
Who sells Lipitor today?
Viatris lists Lipitor among 20 primarily off-patent oral solid dose legacy brands in its Upjohn business. It is a significant product in Greater China and in other Viatris segments. [28]
Jackevicius, C. A., Chou, M. M., Ross, J. S., Shah, N. D., & Krumholz, H. M. (2011). Generic atorvastatin and health care costs. New England Journal of Medicine, 366(3), 201-204. https://pmc.ncbi.nlm.nih.gov/articles/PMC3319770
